Le Lézard
Classified in: Health, Science and technology
Subject: TRI

BerGenBio: Promising Data Highlighting Selective AXL Inhibitor Bemcentinib's Potential to Improve Efficacy of Checkpoint Inhibitors Presented at AACR


BERGEN, Norway, April 18, 2018 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces that promising preclinical data with its lead AXL inhibitor bemcentinib (formerly BGB324) has been presented in a poster at the 2018 American Association for Cancer Research (AACR) Annual Meeting on 14-18 April in Chicago, IL, USA.

The data highlight bemcentinib's potential to reverse tumour immune suppression and enhance immune checkpoint inhibitor efficacy.

The authors show that bemcentinib targets immune suppression mechanisms in the tumour microenvironment that improve immunotherapy in murine tumour models of non-small cell lung (NSCLC), triple negative breast (TNBC) and pancreatic cancer. Bemcentinib treatment reduces myeloid-derived suppressor cells and the altered immune landscape is associated with increased tumour infiltration of T cells (NK and CD8+) and enhanced therapy responses.

A validated AXL immunohistochemistry (IHC) method for use on patient samples to identify the presence of AXL on tumour cells and immune cells in the tumour microenvironment was presented. The authors report that across 92 banked tumour biopsies from patients with TNBC or NSCLC 70% were found to stain positive for AXL using this IHC method. The IHC method is now in use to analyse biopsies taken in connection with the company's phase II combination trials of bemcentinib with KEYTRUDA® in patients with advanced NSCLC or TNBC.

Professor James Lorens, BerGenBio Chief Scientific Officer, commented: "These results highlight a clear and important role for AXL in aggressive disease and resistance to immune therapy in particular. They provide continued confidence in the potential of combining bemcentinib with immune checkpoint inhibitors to improve cancer treatment, and support for our Phase II clinical trial programme of bemcentinib combined with the blockbuster immune checkpoint inhibitor KEYTRUDA, interim results from which are expected during 2018."

The poster is available online - www.bergenbio.com/investors/presentations/

About BerGenBio ASA 

BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors as a potential cornerstone of combination cancer therapy. The Company is a world leader in understanding the essential role of AXL kinase in mediating cancer spread, immune evasion and drug resistance in multiple aggressive solid and haematological cancers.

BerGenBio's lead product, bemcentinib (BGB324), is a selective, potent and orally bio-available small molecule AXL inhibitor in four Company sponsored Phase II clinical trials in major cancer indications, with read-outs anticipated during 2018. It is the only selective AXL inhibitor in clinical development.

The Company sponsored clinical trials are:

The clinical trials combining bemcentinib with KEYTRUDA in adenocarcinoma of the lung and TNBC are conducted in collaboration with Merck & Co., Inc. (Kenilworth, NJ, USA), through a subsidiary.

In addition, a number of investigator-sponsored trials are underway, including a trial to investigate bemcentinib with either MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial combining bemcentinib with docetaxel in advanced NSCLC.

BerGenBio is simultaneously developing a companion diagnostic test to identify patient subpopulations most likely to benefit from treatment with bemcentinib. This will facilitate more efficient registration trials and support a precision medicine based commercialization strategy.

The Company is also developing a diversified pre-clinical pipeline of drug candidates, including BGB149, an anti-AXL monoclonal antibody.

For further information, please visit: www.bergenbio.com  

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered trademark of OSI Pharmaceuticals, LLC., marketed by Roche-Genentech. TAFLINAR® is a registered trademark of Novartis International AG and MEKINIST® is a registered trademark of GSK plc.

Contacts  

Richard Godfrey
CEO
BerGenBio ASA
+47-917-86-304

Rune Skeie
CFO
BerGenBio ASA
[email protected]
+47-917-86-513

Media Relations in Norway

Jan Petter Stiff
Crux Advisors
[email protected]
+47-995-13-891 

International Media Relations

David Dible
Mark Swallow
Marine Perrier
Citigate Dewe Rogerson
[email protected]
+44-207-638-9571

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/bergenbio-asa/r/bergenbio--promising-data-highlighting-selective-axl-inhibitor-bemcentinib-s-potential-to-improve-ef,c2498527

SOURCE BerGenBio ASA


These press releases may also interest you

at 16:05
Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments....

at 16:05
Bristol Myers Squibb today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia (ozanimod) in adult patients with moderate to...

at 16:05
SOFTRAX, a leading provider of cloud-based billing and revenue management solutions, today announced that the SOFTRAX Revenue Management System was named a 2024 SIIA CODiE Award Finalist in the Best Subscription Billing Solution category. CODiE...

at 16:05
Personalis, Inc. , a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time. About Personalis, Inc....

at 16:05
Leafly Holdings, Inc. ("Leafly" or "the Company") , a leading online cannabis discovery marketplace and resource for cannabis consumers, today announced financial results for its fourth quarter and year ended December 31, 2023. "We saw continued...

at 16:05
Achieve Life Sciences, Inc. , a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced fourth quarter and year-end 2023 financial...



News published on and distributed by: